Meet our People

Tobias Guennel, PhD

Senior Vice President, Global Translational Data Services

Distinguished expert working across the pharmaceutical and biotech space, leading regulatory submissions, translational informatics, and biomarker R&D. Clear focus on precision medicine-guided efforts, strategy, and medical device/diagnostic development. Led numerous analytical R&D efforts and developed novel methodologies to harmonize and analyze data from high-throughput assays, translating it to value at the patient level.

Tina Patel, MS, MBA

Area Vice President, Business Development

Healthcare industry veteran serving as the primary business development contact for life sciences clients in New England. Strategist focused on biomarker laboratory solutions for clinical trials across diverse indications. Holds a Master’s in Business Administration from Babson College and a Master of Science from Boston University.

Sven Olek, PhD

Senior Vice President, Research

Inventor, industry expert, founder and leader of Epiontis. Developed the patents forming the basis of Epiontis’s intellectual property. Conducted pre- and postdoctoral research at the Center for Molecular Biology and Biomedicine (ZMBH) of the University of Heidelberg, Germany, and the R.W. Johnson Pharmaceutical Research Institute, San Diego, California, USA. Received a BSc from the Imperial College of Science, Technology, and Medicine, London, and a PhD in Biochemistry from the University of London.

Stephen Rundlett, PhD

Vice President, Bioanalytical Services

Dynamic and diverse experience leading scientific, operational, marketing, and sales efforts for drug development programs. Specialist in the development and oversight of ligand binding and cell-based assays supporting immunogenicity, phamacokinetics, pharmacodynamic biomarkers and neutralizing antibody assessments.

Sofia Baig

General Manager,
Clinical Solutions

Exceptional strategic leader, adept at driving organizational change and delivering top- and bottom-line business growth. Expert in strategic account management, global clinical development operations, and delivering transformational change inclusive of people, processes, and technology. Winner of multiple prestigious awards, including recognition as a 2021 PharmaVoice 100 most inspiring leader in the life sciences industry, and as part of a team, receiving the 2022 Catalyst Award for DEI work focused on improving women’s representation in senior leadership.

Scott Marshall, PhD

Global Head, Translational Data Services and Alliance Management

Industry expert, leading regulatory submissions, translational informatics, and biomarker R&D for pharmaceutical and biotechnology companies. Focus on precision medicine-guided efforts, strategy, and medical device/diagnostic development. Global responsibility for translational informatics R&D efforts. Has led the development of novel methodologies for patient stratification and biomarker guided clinical trial design.

Rob Fannon, MPH, MBA

General Manager, Biospecimen Solutions

Respected veteran of the biospecimen and biomarker laboratory services industry. Honed his expertise through leadership roles in organizations including Roche, Cancer Genetics, and BioServe. Holds a Master of Public Health and a Masters of Business Administration from the Johns Hopkins University.

Rachel Owen, PhD

Vice President, Immunology

Trusted global leader in immune-oncology and infectious disease research. Deep expertise in flow cytometry assay development, cell-based assays and biomarker discovery, clinical sample testing, and validation for early and late phase clinical trials. Client-facing strategist for translational studies.

Matt Arnold

General Manager, Translational Sciences and EVP, Precision for Medicine

Strategic, highly collaborative biotechnology industry veteran, driven by opportunities to bring life-changing therapeutics to patients. Over two decades of global, cross-functional biotech and pharmaceutical experience, across both rapid growth and mature organizations, including leadership positions at AVROBIO, AstraZeneca, and Amgen.

Kennon Daniels, PhD

Senior Director, In Vitro Diagnostics and Quality

Scientific and regulatory in vitro diagnostic authority, specializing in the development of US regulatory strategies and FDA marketing submissions for IVD assays and instruments. Expertise spans all aspects of product development, analytical and clinical trial protocol designs, Q-Submissions, IDEs, de novos, 510(k)s, and pre-market approval platforms.

Joseph Bower, PhD, MBA

Senior Vice President, Laboratory Operations

Experienced senior leader spanning the academic, pharmaceutical, and CRO industries. Specific expertise in biotherapeutics and vaccines for preclinical and clinical development programs and in identifying the appropriate immunochemistry assays for new development programs. Broad record of accomplishment leading global teams, delivering business strategies, developing business, and ensuring operational excellence.

Jay Lezcano

Senior Vice President, Business Development

Clinical research veteran with a focus on strategic initiatives in the laboratory and biospecimen arena. Dedicated to helping pharmaceutical and life sciences clients innovate, develop, and commercialize next generation medical products.

Jared Kohler, PhD

Senior Vice President, Operations & Customer Solutions

Extensive industry expertise across the pharmaceutical and biotech space-translational research, data management, and statistical support-with a focus in precision medicine-guided efforts in drug and diagnostic development. Subject matter expert in genomics. Pioneered approaches in biomarker data management and has led Biometrics operations on over 70 clinical studies.

Deborah Phippard, PhD

Chief Scientific Officer

Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy.

Darren Davis, PhD

Senior Vice President

Visionary leader with more than 25 years of distinguished biotechnology and clinical translational research experience. Founded ApoCell in 2004 and later was instrumental in developing and commercializing the ApoStream® rare-cell liquid biopsy technology. Globally recognized cancer researcher and the author of more than 100 peer-reviewed publications. Dedicated and committed to improving the lives of patients with debilitating diseases.

Cullen Taylor, MD

Medical Director, Biospecimen Solutions

Visionary dedicated to enabling collaborations that help facilitate efficient translational research, discovery and development. Full-time pathologist and founder of the uniquely consultative biospecimens company Glas. Believes that forward-thinking pathologists and laboratorians should play a critical role in realizing the promise of translational medicine.

Crystal Sung, PhD

VP, Companion Diagnostics- Assay Development and Testing

Respected scientist and bioanalytical leader focused on clinical development of companion diagnostics for rare diseases and oncology. American board-certified medical laboratory immunologist. Holds a CLIA high complexity/New York State lab director’s qualification in Diagnostic Immunology and Clinical Chemistry.

Chad Clark

President

Recognized industry leader focused on combining cutting-edge technology, strategic program design, and operational excellence to help life sciences companies effectively address the increasing evidence demands and need to accelerate research initiatives. Previous experience spans the execution of phase I-IV clinical trials, specialty lab services, biospecimen logistics and banking, risk management, and patient support initiatives.

Angélique Heckmann, PhD

Regional Vice President, Translational Business Solutions, Europe & APAC

Passionate leader combining a scientific background in immunology with significant business development experience. Expert at supporting pre-clinical research and biomarker data analysis. Committed to balancing science, team coordination, and communication to achieve excellence in project delivery and accelerate oncology drug development programs.

Angela Brady, MHL

Vice President, Global Head of Project and Alliance Management

Strategic leader and intrapreneurial thinker with extensive experience across pharmaceutical and biotech clinical development and operations. Broad expertise in relationship, risk, and change management; elegant solutioning; and developing leaders. Passionately focused on applying creativity, inspiration, innovation, and vision to our delivery of services.

Andrea Cotton-Berry, MSc

Global Head of Strategic Development, Clinical Solutions

Notable authority in global operations, dedicated to fostering team spirit of excellence and collaboration with internal and external partners. Veteran of the quest to improve oncology therapies and extend lives, including 15+ years in oncology drug development, building on 10 years in obstetrics and women’s health.

Amanda Woodrooffe, PhD

Senior Vice President, General Manager UK Labs

Experienced leader of scientific operations for drug discovery in both the pharmaceutical and CRO industries. Driven to provide actionable data enabling biopharmaceutical research and development. Collaborative partner ensuring licensing and scientific support for corporate development initiatives.

Stephanie O’Reilly, MSOB, SHRM – SCP

Senior Vice President, Human Resources, Precision for Medicine

Seasoned human resources professional, laser-focused on attracting, motivating, and retaining the best possible talent globally. Catalyst for the continued development of a strong performance- and innovation-oriented culture. Proactively aligns HR strategies with the company’s overall business strategy.

Fred Cohen, MD

Co-Founder and Chairman at Monograph Capital Partners and Co-Founder and Senior Managing Director at Vida Ventures

Serial founder of life science-focused investment groups. Leverages expertise gleaned as a research scientist, an internist for hospitalized patients, a consulting endocrinologist, and the Chief of the Division of Endocrinology and Metabolism at the University of California, San Francisco. Graduate of Yale University (BS), Oxford University (DPhil, Rhodes Scholar), and Stanford University (MD).

Matt Hobart

Co-Managing Partner, TPG Growth

Leader of healthcare investments for both TPG Growth and the Rise Fund. Serves on the boards of Precision Medicine Group, Blue Cloud Pediatric Surgery Centers, Center for Health Education and Access, RefleXion Medical, GoHealth Urgent Care, Q-Centrix, Asia Healthcare Holdings, BGB Group, and Evercare Health Holdings. Graduate of Miami University (BA) and Stanford University Graduate School of Business (MBA).

Anushka Sunder

Senior Managing Director and Head of Healthcare Private Equity North America, Blackstone

Leading healthcare investor, also actively involved in technology, media, and consumer opportunities. Serves on the boards of Precision Medicine Group, Advarra, Candle, Medline, HealthEdge, Optiv, and TeamHealth. Executive Sponsor of Blackstone’s Women’s Initiative and on the Blackstone Charitable Foundation Leadership Council. Graduate of Harvard College (BA, Phi Beta Kappa) and Harvard Business School (MBA).

Tony Khoury

Executive Vice President

Life sciences leader focused on biologics and advanced therapies. Deep expertise in small and large molecules, honed through work with a range of life science organizations, from start-ups and academic centers to financial institutions and CMOs/CROs. Spearheaded significant global turnkey facility builds, automation, validation, engineering, and serialization track and trace.

Michael Waters

Vice President, Sales

Corporate strategist focused on leading sales organizations from start-up to scale-up, aligning market penetration strategies with company goals, identifying potential opportunities and qualified targets, analyzing sales trends and metrics, and growing and mentoring a high-performing team.

Shanhong Wan, PhD

Vice President, Bioanalytical Services

Pharmaceutical and CRO industry veteran, focused on bioanalytical method development, method validation and sample analysis for pharmacokinetics, pharmacodynamic biomarkers, immunogenicity, and neutralizing antibody assessments. Leveraging scientific and regulatory expertise, established regulatory-compliant laboratories and led antibody drug development for oncology from early preclinical discovery through clinical trials.

Kurt Langenbach, PhD

Vice President, Frederick, Precision for Medicine

Seasoned biotechnology executive and widely published cellular, microbial, and molecular scientist. Extensive experience leading both government and commercial contracted manufacturing and research across a range of therapeutic areas and a diverse set of biologicals, including BSL-3 and biodefense-related pathogens and organisms.

Sallyanne Williams

Senior Vice President, Head, Global Project Management, Clinical Solutions

Long-standing project management leader dedicated to improving delivery across all phases of product development. Working on a global scale, applies strategic smarts to operational delivery and financial management. Recognized as one of the PharmaVoice 100, some of the industry’s most inspiring people, awarded in the “Change Agent” category.

Leo Tysak

Senior Vice President, Global Quality & Compliance

Long-standing authority in regulated services, from biorepository and central laboratory services to clinical trials, REMS, registry programs, and companion diagnostics. Specialist in the design of quality systems and processes that ensure full conformance with applicable regulations, backed by comprehensive audit processes that ensure ongoing integrity.

Michael Groft

Controller

Long-standing financial management expert. Accounting and finance veteran and former CPA. Responsible for company-wide financial matters, including budgeting, planning, financial reporting, and other financial matters. Dual degrees from the University of Maryland in accounting (BA) and transportation and logistics (BS).

Travis Harrison, PhD

Vice President, Bioassay Solutions

Widely published expert in bioanalytical assay design and validation, with particular emphasis on evaluation of immunogenicity. History of obtaining regulatory approvals on multiple neutralizing antibody assays, used to determine patient eligibility for gene therapy. Expertise in a range of therapeutic areas, including oncology, orphan, and rare disease.

Anshul Mangal, JD

Founder, President, and General Counsel, Project Farma

Groundbreaking biotech entrepreneur and investor, dedicated to delivering transformative treatments to the patients who need them. Pioneered the industrialization of advanced therapies, supporting two FDA-approved cell and gene therapies, created the leading worldwide biologics and advanced therapy engineering consulting firm, and developed the largest cell and gene therapy manufacturing footprint in the world.

John Khoury

Executive Vice President

Veteran in the biotech/pharmaceutical industry and authority in gene and cell therapy facility builds. Trusted strategic partner in make vs buy analysis, site and vendor selection, tech transfer execution strategies, and facility start-ups. Extensive experience with small and large molecules, including biologics and biosimilars.

Jim Watson

Vice President

Long-standing authority in high-purity utilities, large-molecule biological processes, and advanced therapies. Leads large-scale capital projects across engineering, maintenance, and EHS disciplines. Expertise in early-phase manufacturing strategy, conceptual design, user requirement specifications, verification, validation, facility turnover, and facility operations.

Chad Salisbury

Senior Vice President

Respected expert in manufacturing gene therapies, vaccines, sterile injectables, and small molecules. Delivered ~$2B USD of greenfield cGMP manufacturing facilities. Experienced in manufacturing, quality, engineering, and supply chain management with a focus on harnessing gene therapy in the fight against devastating rare and prevalent diseases.

Charlie Harper

Vice President

Expert responsible for four facility start-ups and a consent decree workplan. Focused on gene therapy, microbiome, vaccines, and sterile injectables. Key to the development of a best-in-class nonviral gene therapy to overcome the limitations of viral-based gene therapy. Skilled across TechOps/CMC, including manufacturing, quality, supply chain, and program management.

Adam Pfeiffer

Vice President, Strategy

Seasoned life sciences strategist with an emphasis on engineering and qualification in the advanced therapy and large-molecule biologics spaces. Track record of supporting countless drug manufacturers in bringing life-saving therapies to the market. Drives overall business strategy, aligning with operations, marketing, and business development groups in scaling partnerships.

Mike Winston

Senior Vice President, Finance, Precision for Medicine

Finance business partner adept in executing organic and M&A growth strategies to scale organizations and deliver value creation. Track record of successfully leading teams and organizations through complex finance and operational transformations, integrations, carve-outs, and capital raising for multi-national publicly traded and PE-backed companies.

Carolyn Finke

Vice President, Operations, Precision for Medicine Biospecimen Solutions

Industry veteran operationalizing strategic vision to deliver efficient, cost-effective systems that meet current and future organizational needs. Coordinates cross-departmental workflows and negotiates contracts to optimize and expand specimen supply and delivery. Communicates and drives process improvements by developing and standardizing best practices.

Carolyn Harley, PhD

Senior Vice President, Head, Business & Operational Excellence, Clinical Solutions, Precision for Medicine

Seasoned industry veteran focused on maximizing operational quality and efficiency across clinical research through people, process, and technology. Leads technical and process support for clinical systems, ensures strategic resource management, develops preferred provider relationships, and manages vendor governance activities.

Chris Hadley

Managing Director, Berkshire Partners

Visionary who is laser-focused on healthcare investments. Serves on the boards of Precision Medicine Group, Ensemble Health Partners, IVC Evidensia, and U.S. Anesthesia Partners. Leverages expertise garnered as a consultant in the Private Equity Group at Bain & Company, and in marketing and product development General Mills, ConAgra Foods, and Borden Foods.

John Hubbard, PhD

Chairman of the Precision Medicine Group Board of Directors

Respected corporate executive of the biopharmaceutical, CRO, and pharma-tech service industries. Serves on the boards of Precision Medicine Group, Advarra, Signant Health, Agile Therapeutics, and Science 37. Recognized as one of the PharmaVoice 100, some of the industry’s most inspirational people. Graduate of Santa Clara University (BS) and the University of Tennessee (PhD).

Steve Hirschfeld

Precision Medicine Group Board of Directors

Specialist in building highly valuable companies at the intersection of technology and life sciences, with a focus on meaningful improvements in patient lives. Expertise in all facets of SAAS software company operations, from start-up through IPO. Executive coach and natural leader with the unique ability to create business momentum from ground zero. Graduate of the University of Delaware (BS).

Greg Gara

Senior Vice President, Consulting

Seasoned biotechnology industry leader, most recently focused on gene therapy. Expert in the design, construction, start-up, and licensure of manufacturing facilities worldwide. Responsibilities across TechOps/CMC, including manufacturing, engineering, quality, and program management, both at site and global levels.

Messina Wiley

Vice President, Marketing

Marketing authority focused on developing strategic initiatives that build market value, create new business opportunities, and generate revenue growth. Skilled at analyzing market and buyer needs, competitive landscape, and key differentiators to create a personalized customer experience.

Gene Vodovoz, CPA

Chief Financial Officer, Precision for Medicine

Industry-leading finance executive skilled at driving operational efficiency and aligning strategic corporate objectives to enterprise risk management. Collaborator, building structured relationships between internal departments and customer teams, enhancing profitability while elevating customer satisfaction. Energetic, optimistic manager, empowering people while producing bottom-line results.

Chris Ellis

Regional Vice President,
Strategic Alliances
North America

Seasoned business development expert dedicated to working creatively within sponsors’ operational and financial parameters to bring new oncology and rare disease treatments to patients. Track record in establishing productive long-term relationships. Managed international oncology clinical operations teams, sales and marketing, and laboratory research.

Frances Murphy LLB (Hons)

Regional Vice President,
Clinical Business Solutions
EU & APAC

Leading authority in clinical CROs, focused on client services and regional growth implementation. Dedicated proponent of harnessing truly personalized medicine to develop more effective treatments for patients. Brings that passion to client support.

Teresa Pokladowski, MS

Regional Vice President,
Clinical Business Solutions
North America

Respected business development strategist, building successful clinical programs for clients in Massachusetts. Innovator of fresh approaches to biomarker planning, translational solutions, and clinical study design. Experienced in executing phase 1-4 clinical trials, specialty lab services, companion and in vitro diagnostic strategies, and biomarker data management.

Michael Towse

Vice President,
Business Communications

A dedicated communication specialist with a 20 year background spanning development across a diverse range of CRO environments; from business development to training. A diverse career working through the development of communication material, the delivery of communication and initiatives and time spent on the strategic alignment of sales and marketing strategies to corporate objectives and those objectives central to motivating staff, building teams and driving business forward.

Tania Wiens, MSc., MBA

Regional Vice President, Business Development

Biotechnology industry veteran with dual emphasis on research and business and a focus on translational sciences. Expertise spans biomarkers, oncology and rare disease, diagnostics, and translational medicine. Holds a Master’s in Veterinary Microbiology from the University of Saskatchewan, and an MBA from San Jose State University.

Michael Tarn

Director, Strategic Development

15+ years in healthcare and pharmaceutical practice including clinical undertaking and occupation. Bridging business development efforts and program implementation for successful clinical trial conduct. Serves as the primary business development contact for biotech and pharmaceutical clients for research and clinical trial efforts in the branch of medicine for non-oncological pharmaceutical drug development.

Brad Epstein

SVP, Chief Marketing Officer

Recognized creative leader at traditional, direct and digital marketing agencies producing award-winning work and business results for pharmaceutical companies, financial services, healthcare systems and consumer brands. Branding strategist and lead generation expert for innovative healthcare and life sciences organizations.

Carl Wilks

Senior Vice President, Clinical Trial/Project Management

Thoughtful and collaborative leader with extensive experience of functional management in clinical monitoring and project management across Europe and North America. Expertise in building quality & delivery focused teams to support strategic growth and support client needs. Phase I-IV experience in a wide variety of the therapeutic areas including oncology, vaccines, respiratory and rare disease.

Eeva Laitinen

Vice President, Clinical Solutions, Project and Clinical Trial Management

Extensive experience in leading international Clinical Trial project teams across Europe and APAC in pharmaceutical industry and CRO environment. Reliable and flexible leader in managing execution of global clinical trials.

Agnes Pinnel

Senior Vice President, European Solutions

Industry leader in managing large global clinical trials. Co-founder of Argint International, a CRO providing clinical research and regulatory services to the pharmaceutical industry throughout central and south eastern Europe. Holds a masters in biology from Johannes Gutenberg-University in Mainz, Germany.

Ali Sadighian

Senior Vice President, Business Operations Rare and Orphan Solutions

Accomplished and versatile leader with clinical development and R&D experience gained from academia, biopharma, and several top CROs. Unique skills developed as a laboratory researcher at the UCSD School of Medicine, in quality control in the biotech industry, in clinical operations, and as a senior executive. Dedicated to helping innovative companies bring new therapies to patients and families in greatest need.

Angelina Bisconte

Senior Director, Translational Biology & Biomarker Development

Authority in utilizing human primary biological tissue and cells in research and drug discovery. Developer of translational biomarkers for Phase I/II clinical programs in autoimmunity, inflammation and cancer. Expert in phenotypic cell-based assays using multiple primary cell systems such as T/Th17/T-regs, NK-T, B/Plasma/Plasmablasts, Myeloid cells, Dendritic cells (pDCc/mDCs), and MDSCs. Strategist in multi-parametric single-cell flow cytometry and analysis of flow cytometry data. Broad network of contacts at clinical sites and research hospitals, experienced with IRB submissions and clinical protocols. Scientific leader for Precision’s Biomaterials commercial sourcing.

Elizabeth Ludington, PhD

Senior Vice President, Biometrics Rare and Orphan Solutions

Seasoned veteran of the pharmaceutical and biotech industries both through CROs and sponsor companies. Provides statistical, technical, and strategic expertise for preclinical studies, INDs, Phase I-IV clinical studies, eCTDs, and postmarketing studies. Statistical expertise includes study design, protocol review, and writing and reviewing analysis plans and statistical reports. Skilled at representing clients at meetings with regulatory authorities, and as a statistical consultant for programs at all phases of development.

Jesus Garcia, PhD

Scientific Liaison

Respected scientist and research investigator with expertise spanning biotechnology, medical science, technology development, and data analysis. Partners cross-functionally to identify and advance projects related to validation studies, method development, and reference standards.

Julia Amo, MBA, PMP

Chief Operating Officer, Oncology Solutions

Expert strategist for the pharmaceutical, CRO, and healthcare industries. Offers extensive multi-disciplinary drug development experience at the project, compound, and portfolio levels. Takes a sophisticated approach to the operations, infrastructure, and growth of Precision’s oncology division.

Karen Richards, RAC

Senior Vice President, In Vitro Diagnostics and Quality

Leader and innovator in the GMP/ISO/FDA/EU-regulated in vitro diagnostic (IVD) industry. Spearheads regulatory approvals worldwide for both novel and traditional IVD assays and products, as well as laboratory developed tests in the United States. Builds ground-up quality systems, meeting the requirements of US FDA, ISO 13485, CLIA, and CAP.

Karl Forner, MSc

Senior Director, Europe Lead Informatics

Respected expert in mathematics and fundamental and theoretical computer science. Strong focus on genetics. Developer of innovative bioinformatics algorithms for SNP analyses and genome-wide association studies. Avid proponent of and proactive contributor to the open source community.

Marc Lamarine, PhD

Senior Director, Europe Lead Operations

Distinguished expert in the analysis of large-scale, high-throughput genomics and genetics data. Statistical programmer combining computational and experimental methods in various therapeutic areas, including oncology and autoimmune disease.

Matthew Hall, PhD

Senior Director, Business Development

Influential strategy expert in end-to-end bioinformatics and artificial intelligence solutions for biomarker-guided drug development, maximizing the value and utility of biomarker data in clinical trials, CDx, and diagnostics. Previously CEO of SimplicityBio. Holds a doctorate in molecular and cellular biology from the University of Lausanne.

Patricia Devitt Risse, PharmD

President, Clinical Solutions

Widely respected industry leader and founder of ACT Oncology. Guides strategic protocol design and study optimization on behalf of sponsors. Has extensive experience in Phase I-IV trials for most indications, including solid tumor and hematologic malignancies. Leads integrated teams to combine the strength of biomarker insights with clinical outcome data to optimize the development pathway.

Robert Ott, MBA

Senior Vice President, Business Operations

Vetran with deep knowledge of the contract research/pharmaceutical services industry. Provides project leadership and executive support to clients. Directs operational functions, resourcing, and business strategy internally, structuring oncology operations to match client needs.

Sean Pintchovski, PhD

Director, Neurology Solutions

Trusted leader driving multi-site research programs that leverage proprietary state-of-the-art technologies to identify, validate, and integrate next-generation biomarkers to advance clinical trials for a wide range of neurological indications. Able to generate novel hypotheses, then identify and develop the right methods to answer the right scientific questions.

Steve Dobbin

Senior Vice President, European Solutions

Industry leader with expertise managing large multinational clinical trials in 20+ countries across Europe, North America and APAC. Dedicated to providing quality, flexible and cost-effective solutions for clinical development programs.Co-founder of Argint International, a full-service CRO for phase I-IV clinical research trials. Holds a degree in microbiology from University of Warwick, United Kingdom.

Ulrich Hoffmueller, PhD, MBA

Vice President Immune Monitoring Solutions

Veteran biochemist, industry expert, cofounder of Epiontis. Holds a Master’s in Biochemistry from Humboldt University, a PhD from the Charité University Clinic receiving the Charité Research Award, and an MBA from the Berlin School of Economics and Law, Berlin, Germany.

Al Blunt, MD

Senior Vice President, Medical

Noted authority in the drug development industry. Sought-after strategist providing guidance for and oversight of the design, conduct, and analysis of oncology trials, and hands-on leadership for Precision’s team of oncology medical monitors. Expertise honed in clinical trials from phase 1-3 for a wide variety of anticancer drug classes and cancer types.

Ted Foss, PhD

Senior Director, Biomarker Data Management Systems & Data Integration

Expert in multi-modal data management and analysis, with an extensive background in clinical NGS data. Deep experience developing methods across wide range of commercial, service, and operational verticals in biotech and clinical settings. Holds a doctorate in Biophysics from The Scripps Research Institute.

Katerina Kaleova, MD

Medical Director, Clinical Operations

Leading physician with deep experience in clinical operations and medical monitoring management for phase 1-3 studies across indications, including onco-hematological, rare, cardiological, dermatological, and pulmonological disease trials. Noted medical strategist with excellent understanding of the complete drug development process.

Etleva Pashaj, MD

Vice-President, Medical

Strategic, innovation-driven, drug discovery veteran—and board-certified oncologist—with extensive international (EMA and FDA) regulatory experience. Record of excellence in clinical development, medical monitoring and medical strategy, and managing and mentoring cross-functional and global teams for phase 1-4 onco-hematology studies.

Clare Sarvary Fourrier

Senior Vice President, Global Operational Strategy

Veteran of global oncology clinical operations, with in-depth experience in phase 1-3 oncology and hematology research as well as early-phase studies. Builder of world-class oncology research teams and leader of strategic growth of resources and operations across Europe. Keenly focused on study delivery, mitigation of study risk, and client service.

Veteran expertise from industry leaders in clinical trials, translational science, and transformative data

Meet Our People